REG - Diaceutics PLC - Notice of AGM and Posting of Annual Report

DiaceuticsAnnouncement

25/04/2023 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230425:nRSY4408Xa&default-theme=true

RNS Number : 4408X  Diaceutics PLC  25 April 2023

 

25 April 2023

Diaceutics PLC

("Diaceutics" or "the Company")

 

Notice of AGM and Posting of Annual Report

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), a leading
technology and solutions provider to the pharmaceutical industry, announces
that it has today posted its Annual Report for the year ended 31 December 2022
to shareholders together with the Notice of the 2023 Annual General Meeting
("AGM").

 

The Company will hold its AGM on Thursday 18 May 2023 at 10:30am at First
Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park,
Belfast, County Antrim BT9 6GW.

 

The Annual Report and Notice of AGM are now available on the Company's website
at www.diaceutics.com (http://www.diaceutics.com) .

 

 

Enquiries:

 Diaceutics PLC
 Nick Roberts, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Nick Adams

 Kate Hanshaw

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

 Kinvara Verdon

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the commercialisation of
their precision medicines, enabled by the proprietary DXRX platform.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABLGDSDSDDGXU